ProFactor Pharma LTD | Transforming treatment of haemophilia

ProFactor Pharma

Transforming treatment of haemophilia

ProFactor Pharma Ltd (PFP) is developing factor VIII (FVIII) for the treatment of Haemophilia. Our business is to manufacture low cost recombinant FVIII to a severely undersupplied world market.

More About Us

According to the World Health Organisation (WHO) and the World Federation of Hemophilia around two thirds of the haemophilia patient population receive inadequate or no treatment at all.

Learn About Haemophilia

Recent News

Paul Gerskowitch Joins PFP Board

Nov 15, 2019 | News

Profactor Pharma Ltd is pleased to announce the appointment of Dr V Paul Gerskowitch to its board. Dr Gerskowitch joins the board of Profactor Pharma Ltd as an Investor Director with extensive, board level experience in the life sciences industries. He currently...

PFP secures new investment of £2m to achieve pre-clinical trials

Oct 30, 2019 | News

ProFactor Pharma Ltd (PFP) is set to transform the treatment of ‘Haemophilia A’ following the completion of its latest funding round. PFP has secured new investment of £2m in a funding round lead by the investment syndicate Kelvin Capital and supported by Ingenza Ltd...